Etiology of Lymphopenia in Covid19 Infection

Study of the Etiology of Lymphopenia in Covid19 Viral Infection

Study of the cause of lymphopenia in Covid19 viral infection will be done in 3 cohorts. First cohort will be patients asymptomatic or with mild symptoms. Second cohort will be patients with severe illness and admitted to ICU. Third cohort will be patients critically ill and on artificial ventilation.

Study Overview

• Status: Completed
• Conditions: Lymphopenia
• Intervention / Treatment: Diagnostic test: Complete blood picture, bone marrow aspiration cytology

Detailed Description

Each cohort will include 30 patients. Complete blood count in all patients will be done daily in all patients. Bone marrow aspiration cytology will be done in some selected patients especially those with lymphopenia less than 1000 per cubic mm.

Correlation of the degree of lymphopenia with the status of the patients will be done. Also correlation will be done about the relation of recovery of lymphopenia and status of the patients.

• Study Type: Observational
• Enrollment (Actual): 172

Contacts and Locations

Study Locations

• Egypt
  • Cairo, Egypt
    • National Cancer Institute Cairo university

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Child; Adult; Older Adult
• Accepts Healthy Volunteers: N/A
• Genders Eligible for Study: All

• Sampling Method: Probability Sample

Study Population

All patients admitted with the diagnosis off Covid19 viral infection of all ages and all ethnic backgrounds and agree about the study

Description

Inclusion Criteria:

• Any patient admitted with the diagnosis of Covid19 viral infection

Exclusion Criteria:

• Any patient who died within one day of admission

Study Plan

How is the study designed?

Design Details

• Observational Models: Cohort
• Time Perspectives: Prospective

Number of groups / cohorts

3

Cohorts and Interventions

Group / Cohort	Intervention / Treatment
Asymptomatic or mild symptoms patients patients; Patients with no or mild symptoms and need no respiratory support.	Diagnostic test: Complete blood picture, bone marrow aspiration cytology; none except the regular routine investigations in such cases
Severe symptoms patients; Patients who need admission to ICU because he needs oxygen by nasal canula and needs drugs whether azthromycin or remdesivir according to treatment protocol.	Diagnostic test: Complete blood picture, bone marrow aspiration cytology; none except the regular routine investigations in such cases
Critically ill patients; Patients who need artificial ventilation because of many causes and may need plasma from convalescent patients	Diagnostic test: Complete blood picture, bone marrow aspiration cytology; none except the regular routine investigations in such cases

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Death or recovery	Follow up	Up to 24 weeks

Collaborators and Investigators

• Sponsor: Dr Medhat Khafagy

Study record dates

Study Major Dates

• Study Start (Actual): June 1, 2020
• Primary Completion (Actual): June 1, 2021
• Study Completion (Actual): December 1, 2021

Study Registration Dates

• First Submitted: May 23, 2020
• First Submitted That Met QC Criteria: May 26, 2020
• First Posted (Actual): May 27, 2020

Study Record Updates

• Last Update Posted (Actual): July 20, 2022
• Last Update Submitted That Met QC Criteria: July 19, 2022
• Last Verified: July 1, 2022

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Immunologic Deficiency Syndromes; Immune System Diseases; Hematologic Diseases; Leukopenia; Leukocyte Disorders; Lymphopenia
• Other Study ID Numbers: 201920008.2

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: No

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No